• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Dermata Appoints Life Science Executive Brittany Bradrick to Board of Directors

    1/13/22 8:30:00 AM ET
    $DRMA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $DRMA alert in real time by email

    SAN DIEGO, CA / ACCESSWIRE / January 13, 2022 / Dermata Therapeutics, Inc. (NASDAQ:DRMA) ("Dermata," or the "Company"), a clinical-stage biotechnology company focused on the treatment of medical and aesthetic skin conditions, today announced the appointment of Brittany Bradrick to its Board of Directors and its Audit Committee.

    Dermata Therapeutics, LLC Announced the Addition of Wendell Wierenga, Ph.D. to its Board of Directors

    "I am excited to welcome Brittany to our Board of Directors," commented Gerry Proehl, Dermata's Chief Executive Officer, President, and Chairman. "Brittany brings an immense amount of industry expertise to Dermata and has an accomplished background with over 25 years' experience in finance, strategy, and corporate development for life science companies, with both operational and advisory experience. Brittany's credentials and achievements will greatly benefit our company as we continue to develop our product candidates DMT310 and DMT410 from our Spongilla technology platform."

    Ms. Bradrick has served as the Chief Financial Officer of Neurelis, Inc. since October 2021. Prior to joining Neurelis, Ms. Bradrick was Chief Operating Officer and Chief Financial Officer at ViaCyte. She previously served in strategy and corporate development positions for 10 years at Insulet Corporation as Vice President, Strategy & Corporate Development and at Abbott Diabetes Care as the Head of Global Development. Prior to these positions, Ms. Bradrick was an investment banker for the life science industry at Piper Jaffray, Credit Suisse, and Chase Securities for 10 years. Ms. Bradrick began her career as a Federal Reserve Bank Examiner. Ms. Bradrick holds an M.B.A. from the Johnson Graduate School of Management at Cornell University and a B.S. in Business Administration from the University of Missouri.

    Upon her appointment to the Board of Directors, Ms. Bradrick will join the Audit Committee of Dermata, replacing Dr. Steven Mento. Ms. Bradrick was selected as a director due to her extensive industry and financial experience. Dr. Mento will continue to serve as a director at Dermata, including participation on the Nominating and Corporate Governance Committee.

    About Dermata

    Dermata Therapeutics, Inc. is a clinical-stage biotechnology company focusing on the treatment of medical and aesthetic skin conditions. The Company's lead product candidate, DMT310, is the first product candidate being developed from its Spongilla technology platform. DMT310 is a once-weekly topical product candidate derived from a naturally sourced freshwater sponge with multiple unique mechanisms of action. DMT310 is in clinical development for the topical treatment of acne, psoriasis, and rosacea. Dermata's second product candidate, DMT410, uses its Spongilla technology as a new method for topical intradermal delivery of botulinum toxin for the treatment of multiple aesthetic and medical skin conditions. Dermata is headquartered in San Diego, California. For more information, please visit http://www.dermatarx.com/.

    Forward-Looking Statements

    Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are based on the Company's current beliefs and expectations and new risks may emerge from time to time. Forward-looking statements are subject to known and unknown risks, uncertainties, assumptions and other factors including, but are not limited to, statements related to: the potential development and commercialization of product candidates; the ability of the Company's product candidates to achieve applicable endpoints in clinical trials; whether the results of product candidates will lead to future product development; and whether the Company will have the ability to obtain adequate funding for future development of its product candidates. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks and uncertainties inherent in drug development, approval and commercialization, and the fact that past results of clinical trials may not be indicative of future trial results. For a discussion of these and other factors, please refer to Dermata's filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements are qualified in their entirety by this cautionary statement and Dermata undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof, except as required by law.

    Investors:
    Sean Proehl
    Senior Director, Legal and Business Development
    [email protected]

    SOURCE: Dermata Therapeutics



    View source version on accesswire.com:
    https://www.accesswire.com/683309/Dermata-Appoints-Life-Science-Executive-Brittany-Bradrick-to-Board-of-Directors

    Get the next $DRMA alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DRMA

    DatePrice TargetRatingAnalyst
    9/21/2021$14.00Buy
    Brookline Capital
    9/14/2021$9.00Buy
    Maxim Group
    More analyst ratings

    $DRMA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Life Sciences Virtual Investor Forum: Presentations Now Available for Online Viewing

    NEW YORK, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Life Sciences Virtual Investor Forum, held September 18th are now available for online viewing. REGISTER AND VIEW PRESENTATIONS HERE The company presentations will be available 24/7 for 90 days. Investors, advisors, and analysts may downloadinvestor materials from the company's resource section. Select companies are accepting 1x1 management meeting requests through September 23. Please schedule 1x1 meetings here September 18th PresentationTicker(s)Amplia Therapeutics Limited(OTC:INNMF, ASX: ATX))Kelyniam Global, Inc.(O

    9/18/25 8:35:00 AM ET
    $DRMA
    $INM
    $PETV
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments

    Life Science Virtual Investor Forum Agenda Announced for September 18th

    NEW YORK, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series announced the agenda for the Life Science Virtual Investor Forum to be held September 18th. This event is co-hosted by Zacks SCR. Individual investors, institutional investors, advisors, and analysts are invited to attend. REGISTER HERE It is recommended that investors pre-register and run the online system check to expedite participation and receive event updates. There is no cost to log-in, attend live presentations, or schedule 1x1 meetings with management. Please schedule 1x1 meetings here "We are excited to highlight today's innovators from the life scienc

    9/16/25 11:57:15 AM ET
    $DRMA
    $INM
    $PETV
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments

    Dermata Therapeutics to Present at the Life Sciences Virtual Investor Forum September 18th

    SAN DIEGO, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Dermata Therapeutics to Present at the Life Sciences Virtual Investor Forum September 18th Dermata invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com San Diego, CA, September 16, 2025 -- Dermata Therapeutics, Inc. (NASDAQ:DRMA, DRMAW)) ("Dermata" or the "Company"), a science-driven leader in dermatologic solutions, today announced that Gerry Proehl, Founder and CEO of Dermata, will present live at the Life Sciences Virtual Investor Forum hosted by VirtualInvestorConferences.com, on September 18th, 2025. DATE: September 18th TIME: 11:30 AM ESTLINK: REGISTER HERE

    9/16/25 8:35:00 AM ET
    $DRMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DRMA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Fisher Mary was granted 196,851 shares, increasing direct ownership by 207,212% to 196,946 units (SEC Form 4)

    4 - Dermata Therapeutics, Inc. (0001853816) (Issuer)

    1/23/25 5:04:18 PM ET
    $DRMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SVP, CFO Van Hoose Kyri K. was granted 78,741 shares (SEC Form 4)

    4 - Dermata Therapeutics, Inc. (0001853816) (Issuer)

    1/23/25 5:03:18 PM ET
    $DRMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President, CEO and Chairman Proehl Gerald T was granted 787,402 shares (SEC Form 4)

    4 - Dermata Therapeutics, Inc. (0001853816) (Issuer)

    1/23/25 5:02:08 PM ET
    $DRMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DRMA
    SEC Filings

    View All

    Dermata Therapeutics Inc. filed SEC Form 8-K: Other Events

    8-K - Dermata Therapeutics, Inc. (0001853816) (Filer)

    9/17/25 6:05:11 AM ET
    $DRMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dermata Therapeutics Inc. filed SEC Form 8-K: Other Events

    8-K - Dermata Therapeutics, Inc. (0001853816) (Filer)

    9/10/25 8:00:53 AM ET
    $DRMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dermata Therapeutics Inc. filed SEC Form 8-K: Other Events

    8-K - Dermata Therapeutics, Inc. (0001853816) (Filer)

    8/25/25 5:00:11 PM ET
    $DRMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DRMA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Brookline Capital initiated coverage on Dermata Therapeutics with a new price target

    Brookline Capital initiated coverage of Dermata Therapeutics with a rating of Buy and set a new price target of $14.00

    9/21/21 10:38:17 AM ET
    $DRMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Maxim Group initiated coverage on Dermata Therapeutics with a new price target

    Maxim Group initiated coverage of Dermata Therapeutics with a rating of Buy and set a new price target of $9.00

    9/14/21 10:01:43 AM ET
    $DRMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DRMA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Dermata Therapeutics Inc.

    SC 13G/A - Dermata Therapeutics, Inc. (0001853816) (Subject)

    11/14/24 5:07:13 PM ET
    $DRMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Dermata Therapeutics Inc.

    SC 13G - Dermata Therapeutics, Inc. (0001853816) (Subject)

    2/14/24 3:35:03 PM ET
    $DRMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Dermata Therapeutics Inc.

    SC 13G - Dermata Therapeutics, Inc. (0001853816) (Subject)

    6/1/23 5:23:13 PM ET
    $DRMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DRMA
    Leadership Updates

    Live Leadership Updates

    View All

    Dermata Appoints Life Science Executive Brittany Bradrick to Board of Directors

    SAN DIEGO, CA / ACCESSWIRE / January 13, 2022 / Dermata Therapeutics, Inc. (NASDAQ:DRMA) ("Dermata," or the "Company"), a clinical-stage biotechnology company focused on the treatment of medical and aesthetic skin conditions, today announced the appointment of Brittany Bradrick to its Board of Directors and its Audit Committee."I am excited to welcome Brittany to our Board of Directors," commented Gerry Proehl, Dermata's Chief Executive Officer, President, and Chairman. "Brittany brings an immense amount of industry expertise to Dermata and has an accomplished background with over 25 years' experience in finance, strategy, and corporate development for life science companies, with both opera

    1/13/22 8:30:00 AM ET
    $DRMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dermata Therapeutics, Inc. Announces Appointment of Kyri Van Hoose as Senior Vice President, Chief Financial Officer

    SAN DIEGO, CA / ACCESSWIRE / September 1, 2021 / Dermata Therapeutics, Inc. ("Dermata," or the "Company") (NASDAQ:DRMA)(NASDAQ:DRMAW), a clinical-stage biopharmaceutical company focused on the development of novel dermatology therapies, today announced the appointment of Kyri Van Hoose as Senior Vice President, Chief Financial Officer. Ms. Van Hoose is a strategic and operational finance leader with over 20 years of experience, including more than 15 years in the life sciences industry. Ms. Van Hoose is replacing Thomas Insley, who is retiring as the Company's full time CFO after 6 years, but will continue to work with the Company as a financial consultant."I am very excited to welcome Kyri

    9/1/21 6:00:00 AM ET
    $DRMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DRMA
    Financials

    Live finance-specific insights

    View All

    Dermata Therapeutics Provides Corporate Update and Reports Full Year 2022 Financial Results

    - End of Phase 2 meeting with FDA for DMT310 for moderate-to-severe acne expected in 2Q 2023 -- Initiation of DMT310 Phase 3 clinical trial program in moderate-to-severe acne patients expected in 2H 2023 -- DMT410 partnering discussions ongoing -SAN DIEGO, CA / ACCESSWIRE / February 21, 2023 / Dermata Therapeutics, Inc. (NASDAQ:DRMA, DRMAW))) ("Dermata," or the "Company"), a clinical-stage biotechnology company focusing on the treatment of medical and aesthetic skin conditions, today highlighted recent corporate progress, and reported financial results for the year ended December 31, 2022."We are very excited for what Dermata has planned for 2023 for both our DMT310 and DMT410 programs," sai

    2/21/23 4:05:00 PM ET
    $DRMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results

    - DMT310 Phase 2 topline results in moderate-to-severe rosacea anticipated in December 2022 -- Initiation of DMT310 Phase 3 for moderate-to-severe acne expected in 1H 2023 -SAN DIEGO, CA / ACCESSWIRE / November 10, 2022 / Dermata Therapeutics, Inc. (NASDAQ:DRMA, DRMAW))) ("Dermata," or the "Company"), a clinical-stage biopharmaceutical company focusing on the treatment of medical and aesthetic skin conditions, today highlighted recent corporate progress, and reported financial results for the quarter ended September 30, 2022."I am thrilled with all that Dermata has accomplished so far this year and plan to continue the momentum as we near the announcement of our DMT310 Phase 2 topline result

    11/10/22 5:20:00 PM ET
    $DRMA
    Biotechnology: Pharmaceutical Preparations
    Health Care